News

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™

EVERSANA to provide integrated commercialization services, enhancing launch readiness and market entry for differentiated Cutaneous T-cell Lymphoma therapy CRANFORD, N.J., Oct. 16, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced it has finalized an exclusive agreement with EVERSANA(R), a leading provider of global commercialization services, to...

Read Full Article

EVERSANA Announces Development of End-to-End AI-Powered Life Sciences Marketing Agency Built on Google Cloud Technology

CHICAGO, Aug. 4, 2025 /PRNewswire/ -- EVERSANA(R), a leading provider of commercialization services to the global life sciences industry, today launched a groundbreaking pharmaceutical marketing AI agency running on an end-to-end AI-powered delivery platform built on Google Cloud technology. The AI Agency, actively deployed and validated for multiple pharmaceutical brands, is 80% AI-powered and automated, reducing marketing costs and rapidly accelerating traditional agency operations. "This...

Read Full Article

EVERSANA Announces Enterprise Advancement to 'Pharmatize AI" With the Launch of the EVERSANA AI Accelerator

CHICAGO, July 15, 2025 /PRNewswire/ -- EVERSANA(R), a leading provider of commercialization services to the global life sciences industry, today launched the EVERSANA AI Accelerator, a dedicated center of excellence (COE) focused on the transformation of life sciences commercialization through the power of AI. Under the leadership of Faruk Capan, EVERSANA's Chief Innovation Officer, the EVERSANA AI Accelerator will reimagine every stage of life sciences commercialization through cutting-edge...

Read Full Article

EVERSANA Unveils EVERSANA ORCHESTRATE PV, An AI-Propelled Solution to Shape the Future of Pharmacovigilance

Expert-led AI multi-platform solution to streamline drug safety workflows with unmatched speed, accuracy and quality CHICAGO, July 17, 2025 /PRNewswire/ -- EVERSANA, a leading provider of global commercial services to the life sciences industry, today announced a new milestone to transform pharmaceutical operations with the launch of EVERSANA ORCHESTRATE PV. The unified, AI-propelled solution accelerates critical pharmacovigilance workflows, including literature monitoring and aggregate...

Read Full Article

OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

NEW YORK and CHICAGO, June 10, 2025 /PRNewswire/ -- OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, has selected EVERSANA(R), a leading provider of global commercial services to the life sciences industry, to support the U.S. commercialization of OST-HER2, a novel immunotherapy for recurrent, fully resected, pediatric lung metastatic osteosarcoma. OST-HER2, a Listeria...

Read Full Article

OWP Pharmaceuticals Selects EVERSANA to Support U.S. Launch of SUBVENITE® (lamotrigine) Oral Suspension

Novel therapy for epilepsy and bipolar disorders received FDA approval in September CHICAGO, Oct. 23, 2025 /PRNewswire/ -- OWP Pharmaceuticals, a privately held, commercial-stage neuroscience specialty pharmaceutical company, today announced that EVERSANA(R), a leading provider of commercialization services to the global life sciences industry, will provide U.S. commercialization services for the launch of SUBVENITE(R) (lamotrigine) oral suspension, the company's novel treatment for epilepsy...

Read Full Article